AZD7442
- Generic Name
- AZD7442
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.
- Associated Conditions
- -
- Associated Therapies
- -
AZ's antibody first to be cleared by FDA for COVID prevention
AstraZeneca's Evusheld, an antibody cocktail for COVID-19, is the first in its class authorized by the US FDA for preventing infection in immunocompromised individuals aged 12 and older. It offers an alternative for those unable to mount a strong immune response post-vaccination or receive vaccines. Approved based on the PROVENT study showing a 77% reduction in symptomatic COVID-19 risk, it's also under EU review. The US government has ordered 700,000 doses, valuing over $726 million. Evusheld is also being tested for post-exposure prevention and shows promise against variants including Delta and Omicron.
Clinical Trials Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)
The clinical trials market, valued at USD 39,710.28 million in 2021, is projected to reach USD 52,711.08 million by 2027, growing at a CAGR of 5.05%. Factors driving growth include increased R&D spending, the impact of COVID-19, aging populations, and the rise in chronic diseases. North America leads in market growth due to high R&D expenditure and the prevalence of diseases.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath